Sironax

Sironax is a global clinical-stage biotechnology company committed to promoting healthier aging by discovering and developing novel treatments for degenerative diseases affecting longevity, diseases requiring supportive care, and certain autoimmune immunology and inflammation diseases. Sironax has three proprietary clinical-stage programs with first-in-class or best-in-class assets, and several undisclosed preclinical programs. The company’s research targets key contributors of aging: dysregulated cellular death, uncontrolled inflammation, and disrupted energy homeostasis. Sironax is headquartered in Waltham, Massachusetts, with comprehensive research centers in Beijing and Shanghai, China, and additional operations in Basel, Switzerland and Sydney, Australia. For more information, visit sironax.com.